Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Although Medicare coverage of anti-obesity medicines would be important for all older Americans, it is extra important for Black Americans, who are more likely to be living with obesity.

The Centers for Medicare & Medicaid Services has proposed a rule expanding Medicare and Medicaid patients’ access to anti-obesity drugs such as GLP-1s. Congress is also considering such a move.

The Centers for Medicare and Medicaid Services (CMS) issued guidance allowing for the coverage of anti-obesity medications, but only in cases they are indicated for treating conditions other than o… ...

Medicare covers certain obesity-related treatments like counseling and surgeries but typically not weight loss programs for general health. It also currently doesn’t cover obesity medications ...

Click in for more news from The Hill {beacon} Health Care Health Care The Big Story Trump officials reject Medicare coverage of anti-obesity drugs The Trump administration says it will not move ...

The Medicare prohibition on covering obesity medicines began when the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 was implemented — at a time when obesity was still ...

The Biden Administration released plans for a new rule that would require Medicare and Medicaid to cover anti-obesity medications. But it's not clear if the proposed change will go into effect.

Medicare and Medicaid programs have covered the costs of these drugs, such as Wegovy and Zepbound, when used to treat diabetes, but they currently do not for obesity. Biden's proposals would ...

The new obesity drugs, including Wegovy from Novo Nordisk and Zepbound from Eli Lilly, have been shown to improve health in numerous ways, but legislation passed 20 years ago prevents Medicare ...

The Biden administration proposal on obesity drugs. In November 2024, The Biden administration proposed a rule that would allow both Medicare and Medicaid to cover weight loss drugs beginning in ...

CBO projects that 12.5 million Medicare beneficiaries would be able to receive an anti-obesity medication in 2026 if coverage were expanded. Though it estimates that only about 300,000, or 2%, of ...